Aurora Spine Corporation Announces Participation at the North American Spine Society Annual Meeting

Rhea-AI Summary

Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced its participation in the 2024 North American Spine Society (NASS) Annual Meeting from September 25-28, 2024, at McCormick Place, Chicago. The company will showcase its latest innovations at Booth #4510, including:

• SiLO™ TFX SI Fusion System for sacroiliac joint fusion surgery
• DEXA-C cervical interbody cage system with patented DEXA™ Technology
• Hydra™ and OSTEO-ONYX™ lumbar fusion systems with Rough Surface Technology (RST)
• ZIP-51® Interlaminar Fusion System for minimally invasive L5/S1 fusion

Aurora Spine's executives emphasize the transformative nature of their products, particularly highlighting the DEXA-C implant line as the world's first patient-matched interbody implant system.

Positive

• Participation in a major industry event (NASS Annual Meeting) provides exposure and networking opportunities
• Showcasing innovative products like SiLO™ TFX SI Fusion System and DEXA-C cervical interbody cage system
• DEXA-C implant line is the world's first patient-matched interbody implant system, potentially giving Aurora a competitive edge
• ZIP-51® Interlaminar Fusion System offers minimally invasive L5/S1 fusion without screws, potentially improving patient outcomes

Negative

• None.

Company to Showcase Cutting-Edge Innovations at Booth #4510

CARLSBAD, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery, today announced its participation at the 2024 North American Spine Society ("NASS") Annual Meeting. The event will take place from September 25-28, 2024, at McCormick Place, West Building, in Chicago, Illinois. Aurora Spine will be exhibiting at Booth #4510.

The North American Spine Society is a global multidisciplinary medical society that utilizes education, research, and advocacy to foster the highest quality, ethical, and evidence-based spine care. NASS gathers spine professionals from around the world, offering a unique platform for Aurora to showcase its latest innovations.

At this year’s event, the Company will feature its SiLO™ TFX SI Fusion System for sacroiliac joint fusion surgery and the DEXA-C cervical interbody cage system, powered by Aurora’s patented DEXA™ Technology. This technology offers patient-matched implants designed to align with individual bone density and T-Score, ushering in a new era of personalized spinal care. Aurora will also highlight the new Hydra™ and OSTEO-ONYX™ lumbar fusion systems, promoting Rough Surface Technology (RST), and its ZIP-51® Interlaminar Fusion System, which enables minimally invasive L5/S1 fusion without screws, improving procedural efficiency and patient recovery.

“We are excited to attend NASS 2024 and showcase the cutting-edge products we've developed,” said Trent Northcutt, President and CEO of Aurora Spine. "We’ve brought technologies to market that are transforming spinal surgery, and we can’t wait to share them with the industry."

Laszlo Garamszegi, Chief Technology Officer, added: "We’re particularly excited about the DEXA-C implant line, the world’s first patient-matched interbody implant system. It’s a true game-changer for spine surgeons and their patients."

“It is an honor to collaborate with thought-leading spine surgeons from around the world. It is with their guidance and support that we have brought life-changing technology to patients in need,” said Matthew Goldstone, Chief Commercial Officer.

Visit Aurora Spine at Booth #4510 to witness live demonstrations and engage with the Aurora team on how these innovations reshape spinal surgery.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Contact:

Aurora Spine Corporation

Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com

FAQ

What products will Aurora Spine (ASAPF) showcase at the 2024 NASS Annual Meeting?

Aurora Spine will showcase the SiLO™ TFX SI Fusion System, DEXA-C cervical interbody cage system, Hydra™ and OSTEO-ONYX™ lumbar fusion systems, and the ZIP-51® Interlaminar Fusion System at Booth #4510 during the 2024 NASS Annual Meeting.

When and where is Aurora Spine (ASAPF) participating in the NASS Annual Meeting?

Aurora Spine is participating in the NASS Annual Meeting from September 25-28, 2024, at McCormick Place, West Building, in Chicago, Illinois. They will be exhibiting at Booth #4510.

What is unique about Aurora Spine's (ASAPF) DEXA-C implant line?

Aurora Spine's DEXA-C implant line is described as the world's first patient-matched interbody implant system. It uses DEXA™ Technology to offer implants designed to align with individual bone density and T-Score, enabling personalized spinal care.

How does Aurora Spine's (ASAPF) ZIP-51® Interlaminar Fusion System benefit patients?

The ZIP-51® Interlaminar Fusion System enables minimally invasive L5/S1 fusion without screws, which can potentially improve procedural efficiency and patient recovery time.